RE:RE:Biotech M&A to Boom across a landscape of uncharted markets" One final aspect that should never be underestimated when it comes to deals is the perspective of the Federal Trade Commission (FTC) regarding acquisitions and consolidation. As numerous deals continue to make headlines, it’s reasonable to anticipate heightened scrutiny around antitrust considerations, particularly with the larger transactions that are currently taking place."
[ Something that I have been saying since the FTC came into the picture with the initial Merck/Seagen acquisition, which Merck walked away from, and now the proposed US$43 Billion Pfizer/Seagen M&A deal that the FTC will likely deny - thus steering Pfizer towards a bolt-on acquisition of under US$25 Billion, like that for ONCY. ]